Loading
A phase 2 trial of Olutasidenib in diffuse midline glioma, h3 k27-altered, run by Rigel Pharmaceuticals, now recruiting.
Study of Olutasidenib and Temozolomide in HGG is a phase 2 interventional study registered as NCT06161974 by Rigel Pharmaceuticals, with 60 participants planned, started 2025-02-01 and due to reach its primary completion in 2029-06. Interventions recorded: Olutasidenib + TMZ. Conditions listed: High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares IDH inhibitors, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares IDH inhibitors, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares IDH inhibitors, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares IDH inhibitors, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares IDH inhibitors, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares IDH inhibitors, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares IDH inhibitors, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares IDH inhibitors, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/